Skip to main content
NewslettersWatchlist

Ionis Pharmaceuticals(IONS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low36.56
Day High37.65
Open:37.55
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
GlobeNewswire
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Barchart
Markets Today: Stock Index Futures Add to Record Highs on U.S. Economic Optimism
PR Newswire
Ionis to hold third quarter 2023 financial results webcast
PR Newswire
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
PR Newswire
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
PR Newswire
Ionis to host investor and analyst day event
PR Newswire
Ionis to present at upcoming investor conferences
PR Newswire
Ionis reports second quarter 2023 financial results
PR Newswire
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
PR Newswire
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
Barchart
Stocks Set to Open Higher as Investors Await U.S. Payrolls Data and More Big Tech Earnings
PR Newswire
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
PR Newswire
Ionis to hold second quarter 2023 financial results webcast
PR Newswire
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
PR Newswire
Ionis to present at upcoming investor conference
PR Newswire
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
GlobeNewswire
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
PR Newswire
Ionis prices private placement of convertible senior notes
PR Newswire
Ionis announces proposed private placement of convertible notes
PR Newswire
Ionis announces positive donidalorsen late-stage clinical progress in HAE
PR Newswire
Ionis to host 2023 virtual Annual Meeting of Stockholders
PR Newswire
Ionis to present at upcoming investor conferences
PR Newswire
Ionis reports first quarter 2023 financial results
PR Newswire
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
PR Newswire
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
PR Newswire
Ionis to hold first quarter 2023 financial results webcast
Motley Fool
Could This Rare-Disease Drug Candidate Become a Blockbuster?
PR Newswire
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
PR Newswire
Ionis to present at upcoming investor conferences
PR Newswire
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
PR Newswire
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS

Profile

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.